AU5402096A - Conditional expression system - Google Patents

Conditional expression system

Info

Publication number
AU5402096A
AU5402096A AU54020/96A AU5402096A AU5402096A AU 5402096 A AU5402096 A AU 5402096A AU 54020/96 A AU54020/96 A AU 54020/96A AU 5402096 A AU5402096 A AU 5402096A AU 5402096 A AU5402096 A AU 5402096A
Authority
AU
Australia
Prior art keywords
conditional expression
expression system
conditional
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU54020/96A
Other versions
AU716748B2 (en
Inventor
Laurent Bracco
Fabien Schweighoffer
Bruno Tocque
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Publication of AU5402096A publication Critical patent/AU5402096A/en
Application granted granted Critical
Publication of AU716748B2 publication Critical patent/AU716748B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU54020/96A 1995-03-31 1996-03-29 Conditional expression system Ceased AU716748B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9503841A FR2732348B1 (en) 1995-03-31 1995-03-31 CONDITIONAL EXPRESSION SYSTEM
FR95/03841 1995-03-31
PCT/FR1996/000477 WO1996030512A1 (en) 1995-03-31 1996-03-29 Conditional expression system

Publications (2)

Publication Number Publication Date
AU5402096A true AU5402096A (en) 1996-10-16
AU716748B2 AU716748B2 (en) 2000-03-02

Family

ID=9477639

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54020/96A Ceased AU716748B2 (en) 1995-03-31 1996-03-29 Conditional expression system

Country Status (15)

Country Link
EP (1) EP0817845A1 (en)
JP (1) JPH11503011A (en)
KR (1) KR19980703439A (en)
AU (1) AU716748B2 (en)
BR (1) BR9607928A (en)
CA (1) CA2214451A1 (en)
CZ (1) CZ308097A3 (en)
FR (1) FR2732348B1 (en)
HU (1) HUP9801221A3 (en)
IL (1) IL117713A0 (en)
NO (1) NO974449D0 (en)
SK (1) SK131197A3 (en)
TW (1) TW496873B (en)
WO (1) WO1996030512A1 (en)
ZA (1) ZA962506B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0878546A1 (en) * 1997-04-15 1998-11-18 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin
EP0872552A1 (en) * 1997-04-15 1998-10-21 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or Apoptin
US6881571B1 (en) 1998-03-11 2005-04-19 Exonhit Therapeutics S.A. Qualitative differential screening
FR2775984B1 (en) 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa QUALITATIVE DIFFERENTIAL SCREENING
FR2755144B1 (en) * 1996-10-29 1998-11-27 Rhone Poulenc Rorer Sa SINGLE CHAIN ANTI-P53 ANTIBODY FRAGMENTS AND USE THEREOF
JP2002507117A (en) * 1997-06-04 2002-03-05 オックスフォード・バイオメディカ・（ユーケイ）・リミテッド vector
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
US6479653B1 (en) * 1997-08-26 2002-11-12 Ariad Gene Therapeutics, Inc. Compositions and method for regulation of transcription
AU3587599A (en) * 1997-11-28 1999-06-16 Invitrogen Corporation Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
FR2782732A1 (en) * 1998-08-28 2000-03-03 Transgene Sa INDUCTIBLE EXPRESSION SYSTEM
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
JP2003515323A (en) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド Body
GB0015090D0 (en) * 2000-06-20 2000-08-09 Implyx Ltd Gene-activating conjugates
WO2003045415A2 (en) * 2001-11-26 2003-06-05 University Health Network Self-assembling p53 peptides as gene delivery vehicles
EP1506288B1 (en) 2002-05-10 2013-04-17 Medical Research Council Activation induced deaminase (aid)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0832980B1 (en) * 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5917122A (en) * 1992-08-26 1999-06-29 Byrne; Guerard Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic mice
GB9224784D0 (en) * 1992-11-26 1993-01-13 Univ Dundee Cellular protein
AU684524B2 (en) * 1993-06-14 1997-12-18 Tet Systems Holding Gmbh & Co. Kg Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5866755A (en) * 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
FR2710074B1 (en) * 1993-09-15 1995-12-08 Rhone Poulenc Rorer Sa GRB3-3 gene, its variants and their uses.

Also Published As

Publication number Publication date
KR19980703439A (en) 1998-11-05
CZ308097A3 (en) 1998-01-14
TW496873B (en) 2002-08-01
WO1996030512A1 (en) 1996-10-03
BR9607928A (en) 1998-06-09
MX9706928A (en) 1997-11-29
FR2732348B1 (en) 1997-04-30
SK131197A3 (en) 1998-05-06
NO974449L (en) 1997-09-26
ZA962506B (en) 1996-10-01
CA2214451A1 (en) 1996-10-03
EP0817845A1 (en) 1998-01-14
AU716748B2 (en) 2000-03-02
JPH11503011A (en) 1999-03-23
IL117713A0 (en) 1996-07-23
HUP9801221A2 (en) 1998-08-28
HUP9801221A3 (en) 1999-09-28
FR2732348A1 (en) 1996-10-04
NO974449D0 (en) 1997-09-26

Similar Documents

Publication Publication Date Title
AU7310696A (en) Dsplay system
AU4461996A (en) Conditional access system
AU6936896A (en) Messaging system
AU4605496A (en) Fastening system
AUPN422295A0 (en) Control system
AU1581699A (en) Conditional access system
AU4780896A (en) Core-board
AU1030997A (en) Taphane
AU6899696A (en) Improved process-to-mark control system
AU4348196A (en) Multimedia telemanaging system
AU4996696A (en) 2-benzyl-3-arylbenzothiophenes
AU5402096A (en) Conditional expression system
AU5961396A (en) Video pedobarograph system
AU5147496A (en) Fucopeptides
AU4382896A (en) Acetylimidazobenzodiazepines
AU5108596A (en) Morphine-3-esters
AU1322497A (en) Computing system
AU5013796A (en) Wireclamp
AU5107096A (en) Haemodialyser
AU5404996A (en) Construction system
AU4569496A (en) Tetralinyl- and indanyl-ethylamides
AU4726796A (en) Massage system
AU2161897A (en) Helicopter-airplane
AU2609095A (en) Compartmentalizer
AU4831396A (en) Pyrazolotetracyclines

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired